Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

By Laura Mezquita, É. Auclin, R. Ferrara, M. Charrier, J. Remon, D. Planchard, Santiago Ponce, L. Ares, L. Leroy, C. Audigier-Valette and 12 more. JAMA Oncology, 2018

791 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6629664ed2f76cfa55b76479f9dc30f9e2583073

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “NLR has been considered as a potential dynamic marker but further prospective validations are needed [IV, C] [72, 73].”
• Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy (2018, background): “Furthermore, high lactate dehydrogenase levels and a derived neutrophil to lymphocyte ratio exceeding 3 were recently shown to negatively influence the survival outcome of patients with NSCLC treated with PD-1/ PD-L1 inhibitors.(19) In our analysis, no significant association was found between these”